RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:438274

GCGR-related hyperglucagonemia

low confidenceDisorder

Also known as: Mahvash disease

Publications

4,775

Trials

0

Interventional, condition-specific

Researchers

293

Distinct authors in sample

Gene link

GCGR

Strong

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A rare tumor of pancreas caused by mutations in the GCGR gene characterized by pancreatic alpha cell hyperplasia, pancreatic neuroendocrine tumors and markedly increased serum glucagon levels in the absence of a glucagonoma syndrome. Clinical manifestations may include abdominal pain, pancreatitis, fatigue, diarrhea, and diabetes mellitus.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (6)

MVAH · alpha-cell hyperplasia with glucagonemia · nesidioblastosis alpha cell hyperplasia microglucagonoma and nonfunctioning islet cell tumor · nesidioblastosis alpha cell hyperplasia microglucagonoma and nonfunctioning islet cell tumour · nesidioblastosis, alpha cell hyperplasia, microglucagonoma, and nonfunctioning islet cell tumor · nesidioblastosis, alpha cell hyperplasia, microglucagonoma, and nonfunctioning islet cell tumour

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

No matched interventional trial, but a gene association and an animal model are on record — often described as translation-ready / stalled at the clinical step.

  1. Gene identifiedPresent

    Strong — GCGR

  2. LiteraturePresent

    4,775 matched papers (3,084 in last 10 years) Source

  3. Phenotype characterisedPresent

    17 HPO annotations (e.g. Abdominal pain; Diabetes mellitus; Zollinger-Ellison syndrome) Source

  4. Animal modelPresent

    1 genotype model (Mus musculus) Source

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (GCGR).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

17

Associated phenotypes · MONDO:0018582

  • Abdominal pain
  • Diabetes mellitus
  • Zollinger-Ellison syndrome
  • Increased glucagon level
  • Stomatitis

Showing 5 of 17 — open Monarch for the full list.

Animal models (Monarch / Alliance)

1

Model associations linked to this Mondo ID

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

4,775

4,775 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

4,775 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

3,084 in the last 10 years · low confidence

Phrase hits: 53 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

293

Distinct author names in 53 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Yu R14 papers · 2024

    Division of Endocrinology, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America. run.yu@cshs.org

    Papers in Europe PMC
  2. 02
    Wewer Albrechtsen NJ4 papers · 2025

    Department of Biomedical Sciences; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

    Papers in Europe PMC
  3. 03
    Dean ED3 papers · 2024

    Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

    Papers in Europe PMC
  4. 04
    Holst JJ3 papers · 2022

    Department of Biomedical Sciences; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

    Papers in Europe PMC
  5. 05
    Klöppel G3 papers · 2026

    Institute of Pathology, Technische Universität München, Munich, Germany

    Papers in Europe PMC
  6. 06
    Xu Y3 papers · 2024

    Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China.

    Papers in Europe PMC
  7. 07
    Brosens LAA2 papers · 2025

    Department of Pathology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.

    Papers in Europe PMC
  8. 08
    Charron MJ2 papers · 2024

    Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

    Papers in Europe PMC
  9. 09
    Chen W2 papers · 2024

    Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

    Papers in Europe PMC
  10. 10
    de Herder WW2 papers · 2025

    ENETS Center of Excellence, Section of Endocrinology, Department of Internal Medicine, Erasmus MC Cancer Center, Erasmus MC, Rotterdam, The Netherlands.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

low confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for GCGR-related hyperglucagonemia — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("GCGR-related hyperglucagonemia" OR "Mahvash disease" OR "alpha-cell hyperplasia with glucagonemia" OR "nesidioblastosis alpha cell hyperplasia microglucagonoma and nonfunctioning islet cell tumor" OR "nesidioblastosis alpha cell hyperplasia microglucagonoma and nonfunctioning islet cell tumour" OR "nesidioblastosis, alpha cell hyperplasia, microglucagonoma, and nonfunctioning islet cell tumor" OR "nesidioblastosis, alpha cell hyperplasia, microglucagonoma, and nonfunctioning islet cell tumour") OR ("GCGR" OR "GCGR syndrome" OR "GCGR-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"GCGR-related hyperglucagonemia" OR "Mahvash disease" OR "alpha-cell hyperplasia with glucagonemia" OR "nesidioblastosis alpha cell hyperplasia microglucagonoma and nonfunctioning islet cell tumor" OR "nesidioblastosis alpha cell hyperplasia microglucagonoma and nonfunctioning islet cell tumour" OR "nesidioblastosis, alpha cell hyperplasia, microglucagonoma, and nonfunctioning islet cell tumor" OR "nesidioblastosis, alpha cell hyperplasia, microglucagonoma, and nonfunctioning islet cell tumour"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: MVAH

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (4775) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T16:14:52.534Z